| Sign In to gain access to subscriptions and/or personal tools. |
Integrated Bioassays in Microfluidic Devices: Botulinum Toxin Assays
Sarnoff Corporation, 201 Washington Road, Princeton, NJ
Division of Toxinology and Aerobiology, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD
Sarnoff Corporation, 201 Washington Road, Princeton, NJ A microfluidic assay was developed for screening botulinum neurotoxin serotype A (BoNT-A) by using a fluorescent resonance energy transfer (FRET) assay. Molded silicone microdevices with integral valves, pumps, and reagent reservoirs were designed and fabricated. 1-4Electrical and pneumatic control hardwarewere constructed, and softwarewaswritten to automate the assay protocol and data acquisition. Detection was accomplished by fluorescence microscopy. The system was validated with a peptide inhibitor, running 2 parallel assays, as a feasibility demonstration. The small footprint of each bioreactor cell (0.5cm2) and scalable fluidic architecture enabled many parallel assays on a single chip. The chip is programmable to run a dilution series in each lane, generating concentration-response data for multiple inhibitors. The assay results showed good agreement with the corresponding experiments done at a macroscale level. Although the system has been developed for BoNT-A screening, awide variety of assays can be performed on themicrofluidic chipwith little or nomodification.
Key Words: botulinum neurotoxin serotype A bioassay microfluidic devices detection
This version was published on December
1, 2005 Journal of Biomolecular Screening, Vol. 10, No. 8,
788-794 (2005) This article has been cited by other articles:
|
|
||||||||||||||

